|
| Parameter | Vitamin D group () | Placebo group () | value |
|
| Age (years) | 54.5 ± 9.7 | 51.3 ± 10.0 | 0.041 |
| Males, number (%) | 64 (78.0) | 71 (85.5) | 0.232 |
| Body mass index (kg/m2) | 28.8 ± 4.7 | 29.2 ± 5.1 | 0.635 |
| Diagnosis | | | |
| Dilated cardiomyopathy, number (%) | 34 (41.0) | 41 (50.0) | 0.275 |
| Ischemic cardiomyopathy, number (%) | 46 (55.4) | 35 (42.7) | 0.120 |
| Others, number (%) | 3 (3.6) | 6 (7.3) | 0.328 |
| New York Heart Association Functional Class | | | |
| II | 66 (79.5) | 61 (74.4) | 0.464 |
| III | 17 (20.5) | 21 (25.6) | 0.464 |
| Arterial hypertension, number (%) | 21 (25.3) | 25 (30.5) | 0.491 |
| Listed for heart transplantation, number (%) | 15 (18.1) | 20 (24.4) | 0.346 |
| Diabetes mellitus, number (%) | 24 (28.9) | 14 (17.1) | 0.096 |
| Estimated GFR (mL/min/1.73 m2) | 70.6 ± 22.1 | 78.0 ± 23.1 | 0.073 |
| Medications | | | |
| Beta-Blockers, number (%) | 80 (96.4) | 80 (97.6) | >0.99 |
| ACE inhibitors/ARB blockers, number (%) | 80 (96.4) | 81 (98.8) | 0.620 |
| Aldosterone antagonists, number (%) | 67 (80.7) | 71 (86.6) | 0.401 |
| Loop diuretics, number (%) | 68 (81.9) | 71 (86.6) | 0.522 |
| Thiazide diuretics, number (%) | 22 (26.5) | 24 (29.3) | 0.731 |
| Digoxin, number (%) | 27 (32.5) | 33 (40.2) | 0.334 |
| Calcium antagonists, number (%) | 3 (3.6) | 1 (1.2) | 0.620 |
| Calcium supplement use, number (%) | 1 (1.2) | 2 (2.4) | 0.620 |
| Vitamin D supplement use, number (%) | 0 | 0 | >0.99 |
| Biochemical parameters | | | |
| Calcium (mmol/L) | 2.38 ± 0.11 | 2.38 ± 0.11 | 0.634 |
| Phosphate (mmol/L) | 0.88 ± 0.20 | 0.96 ± 0.22 | 0.026 |
| 25-Hydroxyvitamin D (nmol/L) | 35.9 ± 17.9 | 37.0 ± 16.5 | 0.667 |
| 1,25-Dihydroxyvitamin D (pmol/L) | 83.9 ± 34.3 | 90.1 ± 33.5 | 0.252 |
| Fibroblast growth factor-23 (RU/mL) | 82 (38–194) | 63 (35–137) | 0.330 |
| Renin (mIU/L) | 300 (79–1277) | 297 (141–752) | 0.954 |
| Aldosterone (ng/L) | 120 (70–230) | 160 (103–313) | 0.022 |
|
